Continuation rates of levetiracetam in children from the EULEVp cohort study

Shorvon, 2002, A new antiepileptic drug, J Neurol Neurosurg Psychiatr, 72, 426 EMEA. Keppra® Procedural steps taken and scientific information after the authorisation. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/keppra/H-277-en8b.pdf. Bootsma, 2007, Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center, Epilepsy Behav, 10, 296, 10.1016/j.yebeh.2006.11.016 Chung, 2007, Comparative retention rates and long-term tolerability of new antiepileptic drugs, Seizure, 16, 296, 10.1016/j.seizure.2007.01.004 Depondt, 2006, The long term retention of levetiracetam in a large cohort of patients with epilepsy, J Neurol Neurosurg Psychiatr, 77, 101, 10.1136/jnnp.2005.064626 Kuba, 2006, Long-term levetiracetam treatment of epilepsy patients: clinical audit, Epilepsy Res, 72, 111, 10.1016/j.eplepsyres.2006.07.005 Mohanraj, 2005, Levetiracetam in refractory epilepsy: a prospective observational study, Seizure, 14, 23, 10.1016/j.seizure.2004.02.006 Nicolson, 2004, A prospective analysis of the outcome of levetiracetam in clinical practice, Neurology, 63, 568, 10.1212/01.WNL.0000133214.78602.B3 Peltola, 2009, Retention rates of new antiepileptic drugs in localization-related epilepsy: a single-center study, Acta Neurol Scand Suppl, 119, 55, 10.1111/j.1600-0404.2008.01062.x Simister, 2007, Long-term retention rates of new antiepileptic drugs in adults with chronic epilepsy and learning disability, Epilepsy Behav, 10, 336, 10.1016/j.yebeh.2006.12.005 Droz-Perroteau, 2011, The EULEV cohort study: rates of and factors associated with continuation of levetiracetam after 1 year, Br J Clin Pharmacol, 71, 121, 10.1111/j.1365-2125.2010.03805.x Sander, 2005, New antiepileptic drugs in practice – how do they perform in the real world?, Acta Neurol Scand Suppl, 181, 26, 10.1111/j.1600-0404.2005.00505.x Fattore, 2011, A multicenter, randomized, placebo-controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy, Epilepsia, 52, 802, 10.1111/j.1528-1167.2010.02976.x Glauser, 2002, Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial, Epilepsia, 43, 518, 10.1046/j.1528-1157.2002.13101.x Callenbach, 2008, Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study, Eur J Paediatr Neurol, 12, 321, 10.1016/j.ejpn.2007.09.004 Coppola, 2004, Levetiracetam during 1-year follow-up in children, adolescents, and young adults with refractory epilepsy, Epilepsy Res, 59, 35, 10.1016/j.eplepsyres.2004.03.006 Glauser, 2006, Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures, Neurology, 66, 1654, 10.1212/01.wnl.0000217916.00225.3a Grosso, 2007, Efficacy and safety of levetiracetam in infants and young children with refractory epilepsy, Seizure, 16, 345, 10.1016/j.seizure.2007.02.004 Grosso, 2005, Efficacy and safety of levetiracetam: an add-on trial in children with refractory epilepsy, Seizure, 14, 248, 10.1016/j.seizure.2005.02.004 Lagae, 2005, Clinical experience with levetiracetam in childhood epilepsy: an add-on and mono-therapy trial, Seizure, 14, 66, 10.1016/j.seizure.2004.10.004 Lagae, 2003, Effect of levetiracetam in refractory childhood epilepsy syndromes, Eur J Paediatr Neurol, 7, 123, 10.1016/S1090-3798(03)00041-2 Nakken, 2003, A paradoxical effect of levetiracetam may be seen in both children and adults with refractory epilepsy, Seizure, 12, 42, 10.1016/S1059131102001723 von Stuelpnagel, 2007, Long-term use of levetiracetam in patients with severe childhood-onset epilepsy, Eur J Paediatr Neurol, 11, 341, 10.1016/j.ejpn.2007.02.016 Wheless, 2002, Levetiracetam in refractory pediatric epilepsy, J Child Neurol, 17, 413, 10.1177/088307380201700603 Lee, 2010, Efficacy and safety of adjunctive levetiracetam therapy in pediatric intractable epilepsy, Pediatr Neurol, 42, 86, 10.1016/j.pediatrneurol.2009.08.002 Sharpe, 2008, Levetiracetam monotherapy in juvenile myoclonic epilepsy, Seizure, 17, 64, 10.1016/j.seizure.2007.07.001 Verrotti, 2008, Levetiracetam in juvenile myoclonic epilepsy: long-term efficacy in newly diagnosed adolescents, Dev Med Child Neurol, 50, 29, 10.1111/j.1469-8749.2007.02009.x Verrotti, 2008, Levetiracetam in absence epilepsy, Dev Med Child Neurol, 50, 850, 10.1111/j.1469-8749.2008.03099.x Striano, 2007, An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy, Neurology, 69, 250, 10.1212/01.wnl.0000265222.24102.db Striano, 2008, A pilot trial of levetiracetam in eyelid myoclonia with absences (Jeavons syndrome), Epilepsia, 49, 425, 10.1111/j.1528-1167.2007.01524.x Opp, 2005, Levetiracetam in children with refractory epilepsy: a multicenter open label study in Germany, Seizure, 14, 476, 10.1016/j.seizure.2005.08.002 Peake, 2007, Retention rate of levetiracetam in children with intractable epilepsy at 1 year, Seizure, 16, 185, 10.1016/j.seizure.2006.12.001 Tan, 2004, Efficacy and tolerability of levetiracetam in children aged 10 years and younger: a clinical experience, Seizure, 13, 142, 10.1016/S1059-1311(03)00193-6 Knoester, 2004, Patterns of lamotrigine use in daily clinical practice during the first 5 years after introduction in the Netherlands, J Clin Pharm Ther, 29, 131, 10.1111/j.1365-2710.2004.00544.x 2011